Osimertinib (Tagrisso) for locally advanced or metastatic non-small cell lung cancer, EGFR mutation positive (Ex19del or L858R) - first line

featured image
Therapeutic Areas: Lung and Respiratory Cancer
Year: 2017

Osimertinib is a drug that prevents, inhibits or halts the development of a tumour. It is administered as a tablet. If licensed, osimertinib could offer an additional treatment option for patients with advanced NSCLC that is EGFR mutation positive (Ex19del or L858R) in the first line setting.